AtriCure and Baheal Group Establish Partnership and China
Distribution Agreement

Baheal will serve as the exclusive distribution partner for AtriCure
products across China

June 05, 2018 06:00 AM Eastern Daylight Time

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
management, today announced it has partnered with Baheal Pharmaceutical
Group in China to distribute AtriCure’s surgical ablation devices. This
new multi-year agreement establishes Baheal as the exclusive distributor
for AtriCure, and replaces the company’s previous distributor in China.

“We are pleased to have formed this new partnership with Baheal,” said
Michael Carrel, AtriCure’s President and Chief Executive Officer. “With
Baheal’s stellar reputation, their size and scale, combined with our
market-leading devices, we are well positioned to establish a foundation
for future growth in China.”

AtriCure has been selling its surgical ablation devices in China for the
past 14 years. During that time, several of China’s leading hospitals
have adopted AtriCure devices, and in addition, the company expects to
pursue new product approvals over the next several years to eventually
bring its full portfolio of surgical ablation and left atrial appendage
management devices into the market.

“At Baheal, we’re continuously looking for ways to grow and expand our
business,” said Fu Gang, Chairman of Baheal Pharmaceutical Group. “We
believe that there is vast opportunity to treat patients and the market
remains underpenetrated, and we’re confident that together, we are well
positioned to grow and help more patients in China affected by Atrial
Fibrillation.”

About AtriCure, Inc.

AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage (LAA) Exclusion System products are the most widely sold LAA
management devices worldwide, with more than 125,000 implanted to date.
For more information, visit AtriCure.com or follow us on Twitter
@AtriCure.

About Baheal Group

Founded in 2005, BAHEAL Pharmaceutical Group is a group enterprise
devoted to the resource innovation and integration platform in the
health industry. Driven by the world’s cutting-edge intelligent
information technologies, relying on its superb capability in health
brand operation and management and building on its highly efficient
industry resource integration abilities, the Group has been digging deep
in China’s medical and health care industry for more than a decade,
providing optimized solutions for all links along the big health
industry chain through the global brand ecosystem, intelligent
application ecosystem, medical service ecosystem and investment
ecosystem under its flag.